Description: Neuropathix, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics from its proprietary cannabinoid product platform. It engages in the research and development of chemical entities, such as KLS-13019, as well as its related molecules; and synthetic cannabidiol therapeutics through pre-clinical drug discovery and development processes for use in the disease indications of overt hepatic encephalopathy, chronic traumatic encephalopathy, and chemotherapy induced peripheral neuropathy. The company was formerly known as Kannalife, Inc. and changed its name to Neuropathix, Inc. in November 2020. Neuropathix, Inc. was founded in 2010 and is based in Doylestown, Pennsylvania.
Home Page: neuropathix.com
3805 Old Easton Road
Doylestown,
PA
18902
United States
Phone:
858 883 2642
Officers
| Name | Title |
|---|---|
| Mr. Dean Petkanas | Chairman & CEO |
| Mr. Thomas Evangelos Kikis | Founder, Chief Communications Officer & Director |
| Mr. Mark Corrao | Chief Financial Officer |
| Dr. William A. Kinney Ph.D. | Chief Scientific Officer |
| Dr. Douglas Brenneman Ph.D. | Chief Pharmacologist |
| Mr. Mark McDonnell Ph.D. | Chief Chemist |
Exchange: OTCQB
Country: US
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0 |
| Price-to-Sales TTM: | 0.0522 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 6 |